The hypoglycemia risk stratification tool is based on six variables: previous episodes of hypoglycemia-related hospital utilization, insulin use, sulfonylurea use, ED use in the previous year, chronic kidney disease stage, and age.
The observational analysis compared sodium-glucose co-transporter-2 (SGLT2) inhibitors with other glucose-lowering drugs in patients with type 2 diabetes in Denmark, Norway, and Sweden.
Results from the Diabetes Prevention Program Outcomes Study also showed that metformin was cost-effective compared to placebo for patients at high risk of diabetes.
Patients with type 1 diabetes taking dapagliflozin for 24 weeks had lower HbA1c level, body weight, and insulin dose than those on placebo, according to the industry-funded study.
Despite increasing adoption of insulin pumps and continuous glucose monitors, control of HbA1c hasn't necessarily improved, the authors noted.
Canagliflozin may have lower risk of cardiovascular events compared to placebo, industry-funded study finds
The study found a higher risk of amputation of toes, feet, or legs with canagliflozin than with placebo, with most amputations occurring at the toe or metatarsal.
Among both men and women in Finland, height was inversely associated with two-hour plasma glucose concentration, except among patients with a body-mass index of 35 kg/m2 or more.
The industry-funded study used international data to compare rates of heart failure hospitalization and mortality in patients on sodium glucose cotransporter-2 (SGLT2) inhibitors or other glucose-lowering drugs.
status, comorbid conditions, or glycemic control and highlight the fact that potential overtreatment of diabetes is a widespread issue.
In addition to approved drugs duloxetine, pregabalin, and tapentadol, some benefits were found with venlafaxine, oxcarbazepine, tricyclic antidepressants, tramadol, and botulinum toxin.